REGENTIS BIOMATERIALS LTD. financial data

Symbol
RGNT on NYSE
Location
Or Akiva
Fiscal year end
31 December
Latest financial report
20-F - Q4 2025 - 24 Feb 2026

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5,179,378 shares
Common Stock, Shares, Outstanding 5,179,378 shares 3093%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $7,378,000 USD
Other Assets, Current $240,000 USD -5.1%
Assets $7,618,000 USD 1480%
Accrued Liabilities, Current $1,393,000 USD 24%
Liabilities, Current $2,874,000 USD -56%
Liabilities $2,874,000 USD -56%
Retained Earnings (Accumulated Deficit) $55,794,000 USD -32%
Stockholders' Equity Attributable to Parent $4,744,000 USD
Liabilities and Equity $7,618,000 USD 1480%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 22,500,000 shares 14%
Common Stock, Shares, Issued 5,179,378 shares 3093%
Deferred Tax Assets, Valuation Allowance $11,109,000 USD 24%
Deferred Tax Assets, Gross $11,109,000 USD 24%
Deferred Tax Assets, Operating Loss Carryforwards $48,300,000 USD 24%
Additional Paid in Capital $60,538,000 USD 5710%